- Innoviva Inc.
- Astellas Pharma Inc.
- Eisai Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Takeda Oncology
- Sumitomo Dainippon Pharma Co. Ltd.
- Sunovion Pharmaceuticals Inc.
- OSI Pharmaceuticals LLC
- Daiichi Sankyo Co. Ltd.
- Shionogi & Co. Ltd.
- Merck & Co. Inc.
- Banyu Pharmaceutical Co. Ltd.
- Chugai Pharmaceutical Co. Ltd.
- CV Therapeutics Inc.
- Gilead Sciences Inc.
- Shionogi Inc.
- Genentech Inc.
- Amgen Inc.
- ArQule Inc.
- Affymax Inc.
- Kirin Brewery Co. Ltd.
- Kirin Holdings Co. Ltd.
- Aveo Pharmaceuticals Inc.
- Kyowa Hakko Kirin Co. Ltd.
- Astellas licenses Theravance gram-positive antibiotic; deal terminated
- Eisai buys MGI Pharma
- Takeda to buy Millennium for $8.2bn in cash
- Dainippon Sumitomo to buy Sepracor for $2.55bn
- Astellas makes $52/share cash offer for OSI Pharmaceuticals
- Merck & Co. acquires remaining 49% of Banyu
- Nippon Roche acquires majority of Chugai
- Yamanouchi buys Fujisawa for $7.64bn
- Astellas to offer $981mm cash for CV Therapeutics; withdrawn
- Gilead steps up to buy CV Therapeutics for $20 per share
- Shionogi acquires Sciele Pharma for $1.4bn
- Pfizer acquires Wyeth in $67bn deal
- Roche to gain full ownership of Genentech in $43.7bn deal
- Merck and Schering-Plough to merge in $42bn deal
- Takeda gets Japanese rights to 13 Amgen compounds
- Kyowa Hakko licenses Asian rights to ArQule's ARQ197
- Takeda licenses Affymax's Hematide for Japan; deal ends
- Takeda, Affymax expand Hematide deal; collaboration terminated
- Aveo gets VEGF receptor inhibitor from Kirin Brewery
- Kyowa and Kirin's pharma group to merge
- Daiichi to buy majority of Indian generics giant Ranbaxy
- ArQule gets $75mm up front in two new deals with Daiichi; certain rights returned to ArQule
- Takeda pays $60mm up front for rights to AMAG's Feraheme; rights returned
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.